
PDSB Stock Forecast & Price Target
PDSB Analyst Ratings
Bulls say
PDS Biotechnology is viewed favorably because its lead asset PDS0301 has shown durable and differentiated activity in a difficult MSS/pMMR mCRC liver-metastases setting, including a 6-month ORR advantage, 3 complete responses, and a published OS hazard ratio of 0.30 versus a challenging benchmark. The outlook is further supported by the company’s strategic refocus on PDS0301, which concentrates resources on a broader tumor-localized IL-12 approach while reducing spending on VERSATILE-003 and lowering R&D and G&A after the ~36% workforce reduction and $842K restructuring charge in 3Q26. Financial risk also improved after the up to $22.55M Nant-led PIPE, which followed a 2Q26 cash balance of $5.6M and helped fund the planned Phase 3 submission while reducing, though not eliminating, the financing overhang.
Bears say
PDS Biotechnology is burdened by a weak risk/reward profile because its lead PDS0301 liver-met dataset is nonrandomized, small at 22 patients versus a 20-patient sequential comparator, and the promised 6-month ORR and survival signals may not replicate in a multi-center Ph3 with mature survival data still pending. Regulatory and execution uncertainty are equally severe: the Ph3 design has not yet been accepted by FDA, approval or reimbursement is uncertain, and the regimen relies on hepatic artery pump placement, enrollment pace, and toxicity control that may differ from the NCI experience. Financing is the key gating factor, as the company cannot fund the Ph3 from cash in hand, needs about $15M for the randomized mCRC study and another $15M for operations through the interim analysis, and may face dilution or going-concern risk given the committed $11M milestone closing and sub-$2 share price.
This aggregate rating is based on analysts' research of PDS Biotechnology Corporation and is not a guaranteed prediction by Public.com or investment advice.
PDSB Analyst Forecast & Price Prediction
Start investing in PDSB
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PDS Biotechnology Corporation (PDSB) Forecast
PDSB Analyst Forecast & Price Prediction
Start investing in PDSB
Order type
Buy in
Order amount
Est. shares
0 shares